Sector: Life Sciences

Latest content

Medical device maker is latest to tap secondary market for wireless patents

A recent deal shows that a wider selection of corporates are exploring acquisition opportunities and working with custom R&D labs

08 March 2022

Platform technology owners demand a chunk of Moderna’s covid-19 revenues

Arbutus Biopharma and Genevant Sciences have filed suit against the vaccine innovator

07 March 2022

Broad Institute’s big US CRISPR patent win does little to clear path for Cas9 licensees

As the US and European gene-editing IP landscapes drift further apart, therapeutics companies face difficult freedom-to-operate quandaries

03 March 2022

The life science royalty sales market

Featured in Special Report 2022 Q1: Patent Dealmaking

Some of the highest-value deals in intellectual property today are taking place in the burgeoning marketplace for revenue streams linked to pharmaceutical products

02 March 2022

How manufacturing patents are shaping US biologics strategies

Study reveals the significance of manufacturing IP rights in BPCIA litigation

25 February 2022

California pay-for-delay ruling creates new pharma patent settlement headaches

Dispute resolution teams will want to steer clear of the sunshine state following a recent federal court decision

24 February 2022

Russian Supreme Court rejects Gilead’s decree challenge

In a closely watched case, the Supreme Court has upheld the Civil Code’s prioritising of people’s lives and health during the covid-19 pandemic, over profits lost to patent owners

23 February 2022

More is being done than ever before to monetise neglected pharma IP

Roivant’s most recent spinout shows that it is still on the hunt for deprioritised life sciences patents

22 February 2022

BioNTech confirms it will not enforce covid 19 patents – at least for now

The German biotech company becomes the second mRNA vaccine maker to say it will not take legal action during pandemic

21 February 2022

CAFC patent decision could have major implications for originators and generics

Five takeaways from a Federal Circuit majority decision declining to rehear en banc a skinny label dispute between GSK and Teva

17 February 2022

Unlock unlimited access to all IAM content